Randomized Trialhigh evidence
Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial.
Nature medicine·November 8, 2026·PMID 43000472
Why it mattersHFpEF with obesity is common and difficult to treat; this trial provides mechanistic evidence that semaglutide directly reduces cardiac filling pressures, potentially explaining its symptomatic benefits.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled